Day: May 14, 2025

Correction: Price, amount and settlement date corrected. In relation to Landsbankinn’s covered bond auction yesterday, was a covered bond exchange offering where holders of the series LBANK CB 25 could sell the covered bonds in the series against covered bonds bought in the auction at a predefined clean price of 98.520. The covered bond exchange offering results in Landsbankinn buying ISK 2,340m in the series LBANK CB 25. Settlement will take place on 20 May 2025.

LITTLE ROCK, Ark., May 14, 2025 (GLOBE NEWSWIRE) — Inuvo, Inc. (NYSE American: INUV), a leading provider of artificial intelligence AdTech solutions, announced today that it will be participating in the Ladenburg Thalmann Innovation EXPO25, to be held on May 21, 2025, at Convene, 101 Park Avenue, New York, NY. Richard Howe, Chief Executive Officer of Inuvo, is scheduled to present on Wednesday, May 21st at 11:30 a.m. Eastern Daylight Time. Management will also be available for one-on-one meetings with investors throughout the conference. The Ladenburg Thalmann Innovation EXPO25 is a premier event bringing together a diverse group of innovative companies and institutional investors for a full day of presentations, one-on-one meetings, and networking opportunities. The conference will feature approximately 50 technology companies...

CleanCore Advances Strategic Growth with European Acquisition, GSA Contract Award, and Major Airport Deployment Omaha, NE, May 14, 2025 (GLOBE NEWSWIRE) — CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), developer of patented technology that works as a safe and low-cost replacement for traditional cleaning chemicals, today reported its third quarter 2025 financial results and provided a business update. Recent Business Highlights:Strategic Acquisition: On April 17, 2025, CleanCore announced the successful completion of its acquisition of Sanzonate Europe Ltd. This acquisition significantly strengthens CleanCore’s footprint in Europe, enhances its financial foundation, and provides access to a multi-million-dollar sales pipeline. CleanCore expects the transaction to contribute to near-term revenue...

BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21st at 8:30AM ET. 2025 Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:45AM ET.Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage...

FREMONT, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced that homeowners in all of New York’s major investor-owned electric utility service territories who install Enphase IQ® Batteries can now qualify to enroll in the NYSERDA New York Battery Incentive Program. Qualifying homeowners can receive an upfront payment of up to $6,250 through the program. Homeowners in the Central Hudson, ConEd, NYSEG, National Grid, Orange and Rockland, and Rochester G&E service areas could receive the upfront incentive. Homeowners in the ConEd territory of New York City and Westchester County are eligible for an upfront incentive of $250/kWh, capped at $6,250 per site. For example,...

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7%, 14% and 21% ACESOT-1051, the Phase 1 trial of WEE1 inhibitor APR-1051, continues to advance, with patients now being dosed at 100 mg once daily $19.3 million in cash and cash equivalents as of March 31, 2025, providing runway into early Q2 2026 DOYLESTOWN, Pa., May 14, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy...

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025  Cash and cash equivalents of $101M as of March 31, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) — Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. “We are excited by our progress in 2025,” said Andrew Oxtoby, Chief Executive Officer of Kalaris....

Sakeer Hussain, MD, was honored for his dedication to advancing cancer policy at national and state levels during ASCO’s 2025 Advocacy Summit event COUNCIL BLUFFS, Iowa, May 14, 2025 (GLOBE NEWSWIRE) — Sakeer Hussain, MD, a Board-certified medical oncologist at Heartland Oncology and Hematology, a partner practice of the American Oncology Network (AON), has been recognized as a 2025 Advocacy Champion by the Association for Clinical Oncology (ASCO). The distinction was announced during ASCO’s annual Advocacy Summit held in Washington, D.C. last month.Each year, ASCO selects Advocacy Champions who have demonstrated exceptional commitment to policy advocacy in support of high-quality, equitable cancer care. Honorees actively engage lawmakers at both the state and federal levels, champion legislative priorities, and elevate the voice...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “We made meaningful progress in the first quarter across multiple fronts of our clinical and research programs. In March, we announced the initiation of the expansion arm of our Phase 1b/2 clinical trial of Decoy20. This arm will evaluate Decoy20 in combination with BeOne’s (formerly known as Beigene) PD-1 checkpoint inhibitor, Tislelizumab, with a focus on safety, dose optimization, and early signals of anti-tumor activity....